CL2019003168A1 - Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos. - Google Patents

Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos.

Info

Publication number
CL2019003168A1
CL2019003168A1 CL2019003168A CL2019003168A CL2019003168A1 CL 2019003168 A1 CL2019003168 A1 CL 2019003168A1 CL 2019003168 A CL2019003168 A CL 2019003168A CL 2019003168 A CL2019003168 A CL 2019003168A CL 2019003168 A1 CL2019003168 A1 CL 2019003168A1
Authority
CL
Chile
Prior art keywords
bifunctional chelates
pharmacokinetic
pharmacokinetic improvements
remainder
same
Prior art date
Application number
CL2019003168A
Other languages
English (en)
Spanish (es)
Inventor
Eric Steven Burak
Stuart James Mahoney
Ryan Wayne Simms
John Fitzmaurice Valliant
Alla Darwish
Original Assignee
Centre For Probe Dev And Commercialization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre For Probe Dev And Commercialization filed Critical Centre For Probe Dev And Commercialization
Publication of CL2019003168A1 publication Critical patent/CL2019003168A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2019003168A 2017-05-05 2019-11-05 Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos. CL2019003168A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762502260P 2017-05-05 2017-05-05

Publications (1)

Publication Number Publication Date
CL2019003168A1 true CL2019003168A1 (es) 2020-08-28

Family

ID=64016761

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003168A CL2019003168A1 (es) 2017-05-05 2019-11-05 Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos.

Country Status (15)

Country Link
US (2) US11191854B2 (enExample)
EP (1) EP3619191A4 (enExample)
JP (2) JP7693317B2 (enExample)
KR (1) KR102612882B1 (enExample)
CN (2) CN117603148A (enExample)
AU (3) AU2018261888B2 (enExample)
BR (1) BR112019023246B1 (enExample)
CA (1) CA3062553C (enExample)
CL (1) CL2019003168A1 (enExample)
EA (1) EA201992595A1 (enExample)
IL (1) IL270453B2 (enExample)
MA (1) MA48861A (enExample)
RU (1) RU2019139432A (enExample)
WO (1) WO2018204869A1 (enExample)
ZA (1) ZA201908071B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
WO2018204872A2 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
CA3062553C (en) 2017-05-05 2024-02-06 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
WO2020023092A2 (en) * 2018-04-25 2020-01-30 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
AU2019287595B2 (en) * 2018-04-27 2024-10-31 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
MA54399A (fr) * 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Radioimmunoconjugués et polythérapie à base d'inhibiteur de point de contrôle
WO2020186328A1 (en) * 2019-03-20 2020-09-24 The University Of British Columbia Chelators and methods of making and using same
CA3167409A1 (en) * 2020-01-10 2021-07-15 Fusion Pharmaceuticals Inc. Macrocyclic chelates and uses thereof
KR20220125330A (ko) * 2020-01-10 2022-09-14 퓨전 파마슈티칼즈 인크. 지속 면역요법
KR20220157464A (ko) * 2020-03-23 2022-11-29 퓨전 파마슈티칼즈 인크. Fgfr3-표적화된 방사선면역접합체 및 그의 용도
KR102362962B1 (ko) * 2020-06-12 2022-02-16 (주)미래바이오팜 신규한 화합물 및 이를 함유하는 신경 손상, 신경 질환, 또는 발달 장애에 대한 신경세포의 증식 촉진, 분화, 및/또는 재생을 통한 치료 또는 예방용 약제학적 조성물
EP4190801A4 (en) * 2020-07-29 2024-10-02 Chugai Seiyaku Kabushiki Kaisha METHOD FOR MEASURING THE PHARMACOKINETICS OF A DRUG LABELED WITH A NON-RADIOACTIVE SUBSTANCE
WO2022198319A1 (en) * 2021-03-23 2022-09-29 Fusion Pharmaceuticals Inc. Use of a cold fgfr3-targeting molecule and a fgfr3 targeting radioimmunoconjugate for treating cancer
CN117836011A (zh) * 2021-06-17 2024-04-05 梅约医学教育与研究基金会 将生物制剂与多种螯合剂组合的方法和材料
WO2023164777A1 (en) * 2022-03-04 2023-09-07 Fusion Pharmaceuticals Inc. Gucy2c-targeted radiopharmaceuticals and use thereof
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
KR20250127126A (ko) * 2022-12-21 2025-08-26 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 복수의 킬레이트제와 생물학적 제제를 조합하기 위한 방법 및 재료

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US4889931A (en) 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69024826T2 (de) 1989-02-10 1996-06-27 Celltech Therapeutics Ltd Aza-Macrozyklen und Verfahren zu deren Herstellung
US5053503A (en) 1989-02-17 1991-10-01 Centocor Chelating agents
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US6274713B1 (en) 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
JPH06340556A (ja) 1990-06-18 1994-12-13 Dow Chem Co:The イメージング剤としての大環状アミノホスホン酸錯体の使用
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
EP0646019B9 (en) 1992-06-09 2002-12-18 Neorx Corporation Biotin-DOTA conjugates and their use in pretargeting methods
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
GB9504922D0 (en) 1995-03-10 1995-04-26 Nycomed As Process
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
WO2000076556A2 (en) 1999-06-11 2000-12-21 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
AU2001277488B2 (en) 2000-05-12 2006-05-18 University Hospital Prochelators of radiometal labeled molecules
AU2002249935A1 (en) 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
EP1542709A2 (en) 2002-08-06 2005-06-22 EPIX Pharmaceuticals, Inc. Peptide aggregates
DE10250870A1 (de) 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
JP2006517558A (ja) 2003-02-13 2006-07-27 ブラッコ　イメージング　エッセ　ピ　ア コントラスト増強ｘ線位相画像診断
SI1603598T1 (sl) * 2003-03-19 2009-02-28 Universitaetsspital Basel Radiooznačeni konjugati na osnovi substance P innjihove uporabe
EP1641495A4 (en) 2003-05-23 2009-02-25 Epix Pharm Inc OPTICALLY PURE AND ENRICHED ISOMERS OF CHEATING LIGANDS AND CONTRASTANTS
JP4262545B2 (ja) 2003-07-09 2009-05-13 三菱電機株式会社 カスコード接続回路及びその集積回路
CA2538797A1 (en) 2003-09-12 2005-03-24 Invitrogen Corporation Multiplex binding and activity assays
JP2007514758A (ja) 2003-12-19 2007-06-07 シェーリング　コーポレイション 医薬組成物
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
WO2006015318A2 (en) 2004-07-30 2006-02-09 Biogen Idec Inc. Antibody conjugated to a drug moiety via a poptidic linker
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20060222595A1 (en) 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
WO2007009637A2 (de) 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Deren verwendung als kontrastmittel zur anwendung in der nmr-, rontgen- und radiodiagnostik sowie in der radiotheraphie
US7618957B2 (en) 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2007084264A2 (en) 2005-12-29 2007-07-26 Epix Pharmaceuticals, Inc. Methods for myocardial imaging
WO2007106544A2 (en) 2006-03-15 2007-09-20 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
US7777029B2 (en) 2006-05-02 2010-08-17 San Diego State University (Sdsu) Foundation Bifunctional chelators for sequestering lanthanides
US20080213811A1 (en) 2006-08-11 2008-09-04 Invitrogen Corporation Sensor proteins and assay methods
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0624587D0 (en) 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
JP2010516679A (ja) 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
WO2008134289A2 (en) 2007-04-26 2008-11-06 Mallinckrodt Inc. High relaxivity coordinatively unsaturated lanthanide complexes
ES2676598T3 (es) 2007-08-27 2018-07-23 Liebel-Flarsheim Company Llc Eliminación de sílice a partir de compuestos hidrosolubles mediante nanofiltración y cromatografía en fase inversa
CN101842117A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
DE102008045937B4 (de) 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
US8546531B2 (en) 2008-07-16 2013-10-01 The General Hospital Corporation Methods and reagents for preparing multifunctional probes
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
US20110319339A1 (en) 2008-11-06 2011-12-29 Luisa Bracci Neurotensin-derived branched peptides and uses thereof
WO2010088527A2 (en) 2009-01-30 2010-08-05 Mayo Foundation For Medical Education And Research Peptides and nanoparticles for therapeutic and diagnostic applications
AU2010226479A1 (en) 2009-03-19 2011-09-22 Wyeth Llc Methods for the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7) -en-2-yl)ethyl]phosphonic acid and precursors thereof
US20120107248A1 (en) 2009-07-08 2012-05-03 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
CA2785410A1 (en) 2009-12-23 2011-06-30 Carlos F. Barbas, Iii Tyrosine bioconjugation through aqueous ene-like reactions
WO2011090492A1 (en) 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
EP2397466B1 (en) * 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US12097269B2 (en) 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
WO2012109624A2 (en) 2011-02-11 2012-08-16 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
FR2976825B1 (fr) 2011-06-22 2014-02-21 Total Sa Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers
EP2604281B1 (en) 2011-12-14 2014-07-30 Centre National de la Recherche Scientifique (CNRS) Clicked somatostatin conjugated analogs for biological applications
KR20130083592A (ko) 2012-01-13 2013-07-23 현대약품 주식회사 치환된 피페리딘 유도체 및 이의 제조방법
WO2013148568A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
MX2014015419A (es) 2012-06-14 2015-07-14 Janssen Biotech Inc Tratamiento de celulas pluripotentes.
CN102743770B (zh) 2012-06-18 2017-07-21 申宝忠 一种靶向性分子成像探针及活体分子成像方法
CN104602715A (zh) 2012-09-07 2015-05-06 伯拉考成像股份公司 用于MRI的包含金属两亲配合物的顺磁性固体脂质纳米颗粒(pSLN)
WO2014124307A2 (en) 2013-02-08 2014-08-14 The Regents Of The University Of Michigan Targeted theranostics
EP2994471B1 (en) 2013-05-06 2017-05-17 Merck Patent GmbH Macrocycles as kinase inhibitors
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
US20170050989A1 (en) 2013-12-03 2017-02-23 The General Hospital Corporation Molecular Imaging Probes
FR3015547B1 (fr) 2013-12-20 2016-01-01 Total Sa Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US10744204B2 (en) 2014-04-11 2020-08-18 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
CN106456798B (zh) 2014-04-25 2021-02-12 瑞纳神经科学公司 具有高药物负载的抗体-药物缀合物
AU2015258801B2 (en) * 2014-05-16 2020-10-08 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
WO2016016329A1 (en) 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
DE102014115154A1 (de) 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
EP3702367B1 (en) 2014-11-25 2024-05-15 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
WO2017120193A1 (en) * 2016-01-04 2017-07-13 University Of Kansas Drug delivery compositions and methods
US10758634B2 (en) * 2016-03-18 2020-09-01 Wake Forest University Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography
CN108924931B (zh) * 2017-03-24 2024-05-07 中兴通讯股份有限公司 一种无线资源配置方法、装置及用户设备、网络节点
CA3062553C (en) 2017-05-05 2024-02-06 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
WO2018204872A2 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof

Also Published As

Publication number Publication date
BR112019023246B1 (pt) 2023-11-14
AU2018261888B2 (en) 2022-06-30
ZA201908071B (en) 2023-04-26
IL270453A (enExample) 2020-12-31
JP2020518673A (ja) 2020-06-25
CA3062553C (en) 2024-02-06
JP2023090748A (ja) 2023-06-29
RU2019139432A3 (enExample) 2021-06-16
IL270453B2 (en) 2025-05-01
MA48861A (fr) 2020-04-01
NZ759832A (en) 2025-05-30
US20220054664A1 (en) 2022-02-24
KR102612882B1 (ko) 2023-12-11
RU2019139432A (ru) 2021-06-07
US11191854B2 (en) 2021-12-07
BR112019023246A2 (pt) 2020-05-19
WO2018204869A1 (en) 2018-11-08
CN111263747A (zh) 2020-06-09
EP3619191A1 (en) 2020-03-11
EP3619191A4 (en) 2020-12-16
JP7693317B2 (ja) 2025-06-17
AU2024227706A1 (en) 2024-11-21
EA201992595A1 (ru) 2020-04-21
BR112019023246A8 (pt) 2021-02-23
KR20200006087A (ko) 2020-01-17
AU2022221451A1 (en) 2022-09-22
IL270453B1 (en) 2025-01-01
US20190030194A1 (en) 2019-01-31
CN117603148A (zh) 2024-02-27
AU2018261888A1 (en) 2019-11-28
CN111263747B (zh) 2023-10-27
CA3062553A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
CL2019003168A1 (es) Mejoras farmacocinéticas de quelatos bifuncionales y usos de los mismos.
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MX2024006675A (es) Anticuerpos monoclonales del receptor del factor de crecimiento 1 tipo insulina (igf-1r) y usos de los mismos.
MX384379B (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-fármaco.
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CO2018004152A2 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
CU20150128A7 (es) Conjugados fármaco-anticuerpo
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
MX385823B (es) Conjugados de anticuerpo-farmaco hidrofilicos.
MX375570B (es) Conjugados de pirrolobenzodiazepina
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
CL2016001708A1 (es) Determinantes de respuesta del cáncer a la inmunoterapia
MX370807B (es) Anticuerpos que se unen a axl.
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
MX377396B (es) Compuestos de azapiridona y usos de los mismos.
MX389728B (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
UY36075A (es) Derivados de tubulisina
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CL2020003414A1 (es) Tratamiento antidiabético cardiovascular seguro
MX2020005658A (es) Profarmacos de union a albumina de derivados de auristatina e.